Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA · 2003 · 2.5K citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +16

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

Karen K. Fu, Thomas F. Pajak, Andy Trotti et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 1.4K citations

Medicine, Oncology, Radiation Oncology +17

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 578 citations

Medicine, Oncology, Pharmacology +17

Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseases

Mary-Margaret Chren, Rebecca J. Lasek, Anju Sahay et al. · Journal of Cutaneous Medicine and Surgery · 2001 · 362 citations

Pharmacy, Dermatology, Cosmetic Dermatology +15